Valeant Drug-Price Travails Put Stock at $72 to Damodaran

  • NYU professor says rout leaves shares near fair-value estimate
  • Citron's comparison to Enron is off base, blog posting says

Shares of Valeant Pharmaceuticals International Inc. are approaching fair value after plummeting as much as 72 percent in the past three months, according to Aswath Damodaran, a finance professor at New York University.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.